EGFR/CDK2-IN-1

Cat. No.:	HY-151573
CAS No.:	2841405-96-5
Molecular Formula:	$C_{19}H_{12}BrClO_2$
Molecular Weight:	387.65
Target:	EGFR; CDK
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	EGFR/CDK2-IN-1 (Compound 3b) is an EGFR/CDK2 inhibitor. EGFR/CDK2-IN-1 shows good cytotoxicity against MCF7 and HepG2 cells. EGFR/CDK2-IN-1 can be used in cancer research[1].
IC_{50} & Target	EGFR, CDK-2[1].
In Vitro	EGFR/CDK2-IN-1 (0-20 μM; 48 h) shows excellent activity in both MCF7 and HepG2 with IC_{50} values of 4.1 and 3.5 μM, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity Assay[1]

Cell Line:	MCF7, HepG2 cells
Concentration:	0-20 μM
Incubation Time:	48 h
Result:	Exhibited good cytotoxic activity in breast and liver cancer cells.

REFERENCES

[1]. Altowyan MS, et al. Synthesis, Characterization, and Cytotoxicity of New Spirooxindoles Engrafted Furan Structural Motif as a Potential Anticancer Agent. ACS Omega. 2022 Sep 27;7(40):35743-35754.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA